Trial Profile
A multi-centre, open-label, uncontrolled, phase II study to investigate efficacy and safety of ONO-4538 in malignant pleural mesothelioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms MERIT
- Sponsors Ono Pharmaceutical
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 04 Jun 2019 Results published in the Clinical Cancer Research
- 04 Jun 2019 Status changed from active, no longer recruiting to completed according to results published in the Clinical Cancer Research.